Background: Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease without pharmacological treatment yet. There is also a lack of specific dietary recommendations and strategies to treat the negative health impacts derived from NAFLD. Objective: This scoping review aimed to compile dietary patterns, foods, and nutrients to ameliorate NAFLD. Methods:… Continue reading Dietary Patterns, Foods, and #Nutrients to Ameliorate Non-Alcoholic #Fatty Liver Disease: A Scoping Review
Category: Hepatology
Association of nonalcoholic fatty #liver disease with #colorectal adenomatous #polyps and non-adenomatous polyps: a cross-sectional study
Aim This study aimed to investigate the association between non-alcoholic fatty liver disease (NAFLD) and both colorectal adenomatous polyps and non-adenomatous polyps, in order to provide evidence for the prevention of colorectal cancer (CRC) in patients with NAFLD.Methods A retrospective, cross-sectional study was conducted at the First People’s Hospital of Kunshan, Jiangsu, China. The study included 3028 adults who… Continue reading Association of nonalcoholic fatty #liver disease with #colorectal adenomatous #polyps and non-adenomatous polyps: a cross-sectional study
Jaundice: Understanding The Yellowing Of The Skin And Eyes
Jaundice: Understanding The Yellowing Of The Skin And Eyes Introduction Jaundice is a medical condition characterized by the yellowing of the skin, eyes, and mucous membranes. It occurs due to an excess of bilirubin, a yellow pigment produced during the breakdown of red blood cells. Jaundice can be a sign of underlying medical issues and… Continue reading Jaundice: Understanding The Yellowing Of The Skin And Eyes
Resistant #starch decreases intrahepatic #triglycerides in patients with #NAFLD via gut microbiome alterations
Non-alcoholic fatty liver disease (NAFLD) is a hepatic manifestation of metabolic dysfunction for which effective interventions are lacking. To investigate the effects of resistant starch (RS) as a microbiota-directed dietary supplement for NAFLD treatment, we coupled a 4-month randomized placebo-controlled clinical trial in individuals with NAFLD (ChiCTR-IOR-15007519) with metagenomics and metabolomics analysis. Relative to the… Continue reading Resistant #starch decreases intrahepatic #triglycerides in patients with #NAFLD via gut microbiome alterations
High #parathyroid hormone level as a marker of non-alcoholic #fatty #liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis
Highlights•Studies have shown that high PTH was associated with NAFLD/NASH, although the results from existing studies are inconsistent.•Using systematic review, 10 and 4 studies reported the association of PTH with NAFLD and NASH, respectively.•The meta-analysis suggested that high PTH can be a marker of NAFLD.•The meta-analysis also revealed that high PTH tended to be associated… Continue reading High #parathyroid hormone level as a marker of non-alcoholic #fatty #liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis
Partial MCT1 invalidation protects against diet-induced non-alcoholic fatty liver disease and the associated brain dysfunction
Highlights•Diet-induced NAFLD and associated systemic alterations result in behavioural changes and low-grade brain tissue hypoxia.•Brain hypoxia is likely linked to the induced low-grade brain inflammation, as well as cerebrovascular, glial, and metabolic alterations.•Mct1 haploinsufficient mice are protected from NAFLD and detrimental cerebral alterations.•MCT1 is a potential novel therapeutic target for preventing and/or treating NAFLD and the… Continue reading Partial MCT1 invalidation protects against diet-induced non-alcoholic fatty liver disease and the associated brain dysfunction
Elevated C-reactive protein mediates the liver-brain axis: a preliminary study
BackgroundChronic liver diseases of all etiologies exist along a spectrum with varying degrees of hepatic fibrosis. Despite accumulating evidence implying associations between liver fibrosis and cognitive functioning, there is limited research exploring the underlying neurobiological factors and the possible mediating role of inflammation on the liver-brain axis.MethodsUsing data from the UK Biobank, we examined the cross-sectional association… Continue reading Elevated C-reactive protein mediates the liver-brain axis: a preliminary study
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
BACKGROUNDPegozafermin is a long-acting glycopegylated (pegylated with the use of site-specific glycosyltransferases) fibroblast growth factor 21 (FGF21) analogue in development for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia. The efficacy and safety of pegozafermin in patients with biopsy-proven noncirrhotic NASH are not well established.METHODSIn this phase 2b, multicenter, double-blind, 24-week, randomized, placebo-controlled trial,… Continue reading Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
Association between dietary inflammation index and hypertension in participants with different degrees of liver steatosis
BackgroundThe prevalence of hypertension (HTN) is higher in patients with non-alcoholic fatty liver disease (NAFLD). Inflammation is the key link between HTN and NAFLD. Systemic inflammation can be dramatically increased by inflammatory diet intake. However, whether controlling the inflammatory diet intake in NAFLD patients could affect the occurrence of HTN still remains unknown. Our aim… Continue reading Association between dietary inflammation index and hypertension in participants with different degrees of liver steatosis
2 Medical News 